Mylan Institutional Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MYLAN INSTITUTIONAL, and what generic and branded alternatives to MYLAN INSTITUTIONAL drugs are available?
MYLAN INSTITUTIONAL has forty-six approved drugs.
Summary for Mylan Institutional
| US Patents: | 0 |
| Tradenames: | 41 |
| Ingredients: | 39 |
| NDAs: | 46 |
| Patent Litigation for Mylan Institutional: | See patent lawsuits for Mylan Institutional |
| PTAB Cases with Mylan Institutional as petitioner: | See PTAB cases with Mylan Institutional as petitioner |
Drugs and US Patents for Mylan Institutional
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan Institutional | BIVALIRUDIN | bivalirudin | INJECTABLE;INTRAVENOUS | 202471-001 | Jun 1, 2018 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Mylan Institutional | AZACITIDINE | azacitidine | POWDER;INTRAVENOUS, SUBCUTANEOUS | 204949-001 | Apr 28, 2016 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Mylan Institutional | ISOSULFAN BLUE | isosulfan blue | INJECTABLE;INJECTION | 090874-001 | Jul 20, 2010 | AP | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Mylan Institutional | IBUTILIDE FUMARATE | ibutilide fumarate | INJECTABLE;INJECTION | 090924-001 | Jan 11, 2010 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Mylan Institutional | DEXMEDETOMIDINE HYDROCHLORIDE | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 202881-001 | Aug 18, 2014 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Mylan Institutional
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Mylan Institutional | ULTIVA | remifentanil hydrochloride | INJECTABLE;INJECTION | 020630-002 | Jul 12, 1996 | 5,019,583*PED | ⤷ Try a Trial |
| Mylan Institutional | ULTIVA | remifentanil hydrochloride | INJECTABLE;INJECTION | 020630-001 | Jul 12, 1996 | 5,466,700*PED | ⤷ Try a Trial |
| Mylan Institutional | ENLON-PLUS | atropine sulfate; edrophonium chloride | INJECTABLE;INJECTION | 019677-001 | Nov 6, 1991 | 4,952,586 | ⤷ Try a Trial |
| Mylan Institutional | RIMSO-50 | dimethyl sulfoxide | SOLUTION;INTRAVESICAL | 017788-001 | Approved Prior to Jan 1, 1982 | 3,549,770 | ⤷ Try a Trial |
| Mylan Institutional | ULTIVA | remifentanil hydrochloride | INJECTABLE;INJECTION | 020630-001 | Jul 12, 1996 | 5,866,591*PED | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for MYLAN INSTITUTIONAL drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 100 mg/mL, 2.5 mL vials | ➤ Subscribe | 2007-09-24 |
| ➤ Subscribe | for Injection | 1 mg/vial, 2 mg/vial and 5 mg/vial | ➤ Subscribe | 2013-12-27 |
| ➤ Subscribe | Injection | 1 mg/mL, 50 mL vials | ➤ Subscribe | 2011-12-16 |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
